“The EMA has not set age and sex conditions for this type of adenoviral vector vaccine. Our agency has foreseen a preferential use over the age of 60, it does not mean excluding other choices”. This was stated by Giorgio Palù, virologist and president of the Italian drug agency (Aifa), in an interview with ‘Corriere della Sera’ answering the question whether Aifa will also open to the administration of the AstraZeneca and J&J vaccines under the age of 60. But would it be advisable to direct young people to other products? “The benefits of AstraZeneca – warns Palù – always outweigh the risks, from 18 years upwards, but administration at a young age should be considered very carefully taking into account the events of deep vein thrombosis with platelet deficiency reported especially in people under 60. years”.